← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Semax × Selank × DSIP × 3 of 4 selected View comparison

Semax

Synthetic ACTH-fragment analogue

Remove
VS

Selank

Synthetic tuftsin analogue

Remove
VS

DSIP

Neuropeptide

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target SemaxSelankDSIP
✓ — —
— ✓ —
— — ✓

What These Compounds Share

Shared research line

All selected compounds are catalogued under Neuro.

Shared pathway tags
CNS

Key Differences

Semax BDNF-associated is a direct target of Semax that none of the other selected compounds share. An ACTH-derived neuropeptide analogue associated with neurotrophic/neurovascular research.
Selank Neurotransmitter-associated is a direct target of Selank that none of the other selected compounds share. A tuftsin-derived neuroactive peptide, distinct from the ACTH-derived Semax.
DSIP Neuroendocrine-associated is a direct target of DSIP that none of the other selected compounds share. A historically sleep-associated neuropeptide with an incompletely established mechanism -- the name does not indicate proven clinical sleep induction.

Compound Detail

Semax
What is it?
A lab-made peptide related to a natural hormone fragment, studied for brain-related effects.
What are people researching/using it for?
Studied for cognitive and neurological support, mainly in research from Russia.
Other uses being trialed
Stroke recovery researchGeneral brain-health research
Worth knowing
A substantial amount of the literature originates from Russia and has comparatively limited independent international replication. Its stroke-recovery research (see sources) is Russian clinical-trial literature specifically -- real controlled human trials, but from a single research tradition not yet widely replicated internationally.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
An ACTH-derived neuropeptide analogue associated with neurotrophic and neurovascular research.
Heptapeptide · 7 amino acids · Synthetic analogue of an ACTH fragment
Primary Targets & Biological System
Neurotrophic / CNS signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
An analogue of ACTH(4-10), a fragment of adrenocorticotropic hormone that itself has no hormonal (steroidogenic) activity -- Semax's research interest is entirely in proposed neurological effects rather than the endocrine axis ACTH is normally associated with. Multiple, non-mutually-exclusive mechanisms have been investigated, including effects on BDNF and other neurotrophin signalling (proteins supporting neuron growth and survival), dopaminergic and serotonergic neurotransmitter systems, and broader gene-expression changes in neural tissue. No single one of these is treated as the definitive mechanism in the literature, and much of the research base originates from a single geographic research tradition with limited independent international replication.
Research Areas
NeurobiologyNeurotrophic signallingIschaemia/stroke researchCognitive neuroscienceGene-expression research
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Not displayed as a universal human value without a direct source.
Research Routes
Intranasal (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
An ACTH-derived neuropeptide analogue associated with neurotrophic/neurovascular research.
Considerations
Research Limitations
A substantial amount of the literature originates from Russia and has comparatively limited independent international replication. Its stroke-recovery research (see sources) is Russian clinical-trial literature specifically -- real controlled human trials, but from a single research tradition not yet widely replicated internationally.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

ADHD / attention research
Small Russian studies have investigated Semax for attention-related outcomes, consistent with its proposed neurotrophic/dopaminergic mechanism. Limited independent replication outside that research tradition.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Semax · A$69.95 A$89.95
Browse products →
View Research Sources (2) →
[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 1997 · Human Human · 30 patients (acute hemispheric ischemic stroke) treated with Semax; 80-patient conventional-therapy comparison group · PMID 11517472

Russian clinical trial literature. Semax added to intensive therapy increased regression of general cerebral and focal (especially motor) neurological deficits, assessed via clinical scales, EEG mapping and somatosensory evoked potentials. Most effective doses 12-18 mg/day for 5-10 days.

Supports: research_areas, human_administration_status

[The efficacy of semax in the treatment of patients at different stages of ischemic stroke]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2018 · Human Human · 110 patients after ischemic stroke (43 men, 67 women, mean age 58.0±9.7), split into early vs. late rehabilitation groups · PMID 29798983 · DOI 10.17116/jnevro20181183261-68

Russian clinical trial literature. Semax increased plasma BDNF regardless of rehab timing; higher BDNF correlated with better Barthel Index outcomes, and earlier rehab correlated with better motor recovery.

Supports: research_areas, mechanism_summary

Selank
What is it?
A lab-made peptide related to a natural immune signal, studied for calming/CNS effects.
What are people researching/using it for?
Studied for stress and anxiety-related research.
Other uses being trialed
General cognitive-support research
Worth knowing
Human research comes from Russian clinical trials (roughly 60-70 patients per study across three identified trials) comparing Selank against established anxiolytics (phenazepam, medazepam) -- real controlled human evidence, but from a single research tradition with limited independent international replication, and across at least two distinct diagnostic populations (phobic-anxiety/somatoform disorders in one trial; generalized anxiety disorder/neurasthenia in another) that should not be treated as interchangeable.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A tuftsin-derived neuroactive peptide researched in anxiety/stress-related neurobiology.
Heptapeptide · 7 amino acids · Synthetic analogue of tuftsin
Primary Targets & Biological System
CNS / stress signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A synthetic analogue of tuftsin, an immune-signalling tetrapeptide -- but Selank's own research interest is centred on proposed CNS effects rather than tuftsin's immunological role. Multiple neurotransmitter-system and gene-expression mechanisms have been proposed in the literature -- similarly to Semax, no single definitive receptor is asserted, and the mechanistic picture should be read as several parallel hypotheses rather than one confirmed pathway.
Research Areas
Anxiety/stress-related neurobiologyCNS signallingNeurotransmitter systemsImmune-neural signalling
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Not adequately established
Research Routes
Intranasal (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A tuftsin-derived neuroactive peptide, distinct from the ACTH-derived Semax.
Considerations
Research Limitations
Human research comes from Russian clinical trials (roughly 60-70 patients per study across three identified trials) comparing Selank against established anxiolytics (phenazepam, medazepam) -- real controlled human evidence, but from a single research tradition with limited independent international replication, and across at least two distinct diagnostic populations (phobic-anxiety/somatoform disorders in one trial; generalized anxiety disorder/neurasthenia in another) that should not be treated as interchangeable.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Generalized anxiety disorder
Russian clinical trials have directly compared Selank with established anxiolytics: one trial (60 patients with phobic-anxiety/somatoform disorders) compared Selank with phenazepam; a separate trial (62 patients with generalized anxiety disorder and neurasthenia, 30 on Selank/32 on medazepam) found similar anxiolytic effects with additional antiasthenic/psychostimulant effects for Selank; a third trial (70 patients) tested Selank added to phenazepam rather than a head-to-head comparison, and found the combination reduced phenazepam's side effects. Same limited-replication caveat applies as with Semax -- this is a real, controlled evidence base, but from a single research tradition.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Selank · A$69.95 A$79.95
Browse products →
View Research Sources (3) →
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2014 · Human Human · 60 patients with phobic-anxiety and somatoform disorders (ICD-10 F40.2-9, F41.1-9, F45.0-1) · PMID 25176261

Russian clinical trial literature, head-to-head vs. phenazepam. Selank showed pronounced anxiolytic and mild nootropic effects, persisting up to a week after the last dose.

Supports: experimental_research, human_administration_status

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2008 · Human Human · 62 patients with generalized anxiety disorder and neurasthenia (30 Selank, 32 medazepam) -- a distinct diagnostic population from the phobic-anxiety/somatoform study above · PMID 18454096

Randomized, head-to-head vs. medazepam. Anxiolytic effects similar between arms; Selank additionally showed antiasthenic and psychostimulant effects. Reduced leu-enkephalin half-life correlated with disease severity and improved with Selank treatment.

Supports: experimental_research, human_administration_status

[Optimization of the treatment of anxiety disorders with selank]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2015 · Human Human · 70 patients total with anxiety-phobic, hypochondriac and somatoform disorders: 30 on phenazepam monotherapy, 40 on Selank + phenazepam combination · PMID 26356395

NOT a head-to-head Selank-vs-phenazepam comparison -- this tests Selank as an add-on to phenazepam vs. phenazepam alone. Combination produced earlier improvement and reduced phenazepam's side effects (attention/memory impairment, sedation, sexual disturbance) both during and after tranquilizer withdrawal.

Supports: experimental_research

DSIP
What is it?
An older, not-well-understood peptide originally linked to sleep research.
What are people researching/using it for?
Historically studied for sleep -- though the evidence for this is weak and disputed.
Other uses being trialed
General stress-response research -- mechanism remains unclear
Worth knowing
A published human double-blind insomnia study reported statistically significant effects described by the study's own authors as weak, with some possibly attributable to incidental changes in the placebo group rather than a true drug effect. A separate review has questioned the underlying biological interpretation of DSIP altogether. This uncertainty is deliberately not smoothed over here -- its historical name should not be taken to imply clinically proven sleep induction.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A historically sleep-associated neuropeptide with an incompletely established mechanism.
Nonapeptide · 9 amino acids · Originally isolated as an endogenous neuropeptide
Primary Targets & Biological System
Sleep / neuroendocrine signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Despite being named for an early finding of sleep-associated activity, DSIP does not have a definitively established receptor or mechanism in the literature. The "Neuroendocrine-associated" label shown above is not a confirmed binding target -- it reflects only the broad research area its proposed effects have touched on, because no specific receptor has been reliably confirmed for DSIP. A 2006 review specifically questioned the biological basis for treating DSIP as a coherent, receptor-mediated "sleep peptide" at all. This mechanistic uncertainty is a central, not peripheral, fact about this compound.
Research Areas
Sleep physiologyNeuroendocrine signallingStress physiologyCNS research
Research Profile
Human administration: Limited Preclinical: Available
Pharmacokinetics
Not adequately established
Research Routes
Not established in humans (descriptive only — not administration or dosing guidance)
Key Differentiator
A historically sleep-associated neuropeptide with an incompletely established mechanism -- the name does not indicate proven clinical sleep induction.
Considerations
Research Limitations
A published human double-blind insomnia study reported statistically significant effects described by the study's own authors as weak, with some possibly attributable to incidental changes in the placebo group rather than a true drug effect. A separate review has questioned the underlying biological interpretation of DSIP altogether. This uncertainty is deliberately not smoothed over here -- its historical name should not be taken to imply clinically proven sleep induction.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
DSIP · A$84.95 A$99.95
Browse products →
View Research Sources (2) →
Review questioning the biological interpretation of DSIP
Review / secondary literature · PMID 16539679

Supports: mechanism_summary, research_limitations

Human double-blind insomnia study
Human Human · PMID 1299794

Authors reported the statistically significant effects were weak, with some possibly attributable to incidental placebo-group changes.

Supports: research_limitations, human_administration_status

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.